TRIB

Business Context and Reporting Period

Company: Trinity Biotech plc
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2013
Business Overview: Trinity Biotech develops, manufactures, and markets medical diagnostic products for clinical laboratory and Point-of-Care (POC) segments globally. The company operates in approximately 110 countries with manufacturing facilities in Ireland, the UK, and the USA. Key product areas include infectious diseases, autoimmune disorders, diabetes monitoring, and blood bank screening.

Key Financial Metrics (Year Ended Dec 31, 2013)

Note: The company has no bank borrowings. Cost of sales for 2013 includes a US$691,000 Medical Device Excise Tax.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 11% to $91.2 million, driven by Clinical Laboratory growth (12.8%) and Point-of-Care growth (3.1%).
• Profit Decline: Operating profit decreased 47.6% to $9.0 million, and Net Profit decreased 44% to $9.6 million.
• Acquisitions: The company acquired Immco Diagnostics Inc. ($32.9 million) and the blood bank screening business of Lab21 Ltd ($7.5 million) in 2013. These contributed incremental revenue but also increased costs.
• Margin Compression: Gross margin declined to 49.6% due to the new US Medical Device Excise Tax, lower-margin instrument sales, and higher running costs at newly acquired UK facilities.
• SG&A Increase: Selling, General, and Administrative expenses rose 47.5% to $33.1 million. This was primarily due to a $5.4 million charge for an HIV-2 patent license (expensed as no future economic benefit was deemed likely), $0.7 million in restructuring costs for UK operations, and integration costs from acquisitions.
• Cash Flow: Cash generated from operations dropped to $8.8 million from $18.8 million in 2012, largely due to increased working capital outflows (inventory and receivables) and lower operating profit.

Guidance, Outlook, and Risks

• Outlook: Management expects to close the two UK blood bank manufacturing facilities in 2014 to transfer production to Ireland and New York, aiming for operational synergies. The company received CE marking for its Troponin I point-of-care test (Meritas) in January 2014, with FDA submission expected later in the year.
• Dividends: A final dividend of 20 cents per ADS was paid in 2013. A dividend for the 2013 financial year will be proposed at the June 2014 AGM.
• Key Risks:
  • Regulatory: Dependence on FDA and other regulatory approvals for new products (e.g., Troponin I).
  • Competition: Intense competition from large diagnostics firms (Abbott, Roche, Siemens) and risk of technological obsolescence.
  • Intellectual Property: Risks related to patent infringement claims and the ability to protect proprietary rights.
  • Supply Chain: Reliance on third-party suppliers for raw materials (antibodies, antigens) and concentration of manufacturing in specific facilities.
  • Currency: Exposure to fluctuations between the US Dollar and Euro, as well as Swedish Krona and Sterling.

Investor Verification Checklist

• Acquisition Integration: Verify the timeline and cost savings associated with closing the UK blood bank facilities and transferring production to Ireland/USA.
• HIV-2 License Strategy: Confirm the commercial strategy for the UniGold HIV-2 product given the $5.4 million license cost was expensed rather than capitalized.
• Working Capital Management: Monitor the trend in Days Sales Outstanding (DSO) and inventory levels, which drove significant cash outflows in 2013.
• Regulatory Approvals: Track the FDA submission and approval status of the Meritas Troponin I test and other POC products in the pipeline.
• Deferred Tax Assets: Review the realization of unrecognised deferred tax assets, particularly those related to net operating losses in the US, UK, and Sweden.